Community Practice Connections™: Improving Outcomes in MDS and MPN: Tailoring Treatment Based on Patient- and Disease-Specific Factors

Release Date: January 28, 2021
Expiration Date: January 28, 2022

Activity Overview

Treatment options for patients with myeloproliferative neoplasms (MPNs) and myelodysplastic syndromes (MDS) have changed rapidly in recent years for patients across the spectrum of risk stratification. The identification of gene markers including JAK2 and CALR have led to significant advances in the diagnosis and treatment of MPNs, while an increasing understanding of molecular alterations in MDS has affected optimal disease management as well.

This Community Practice Connection™ program provides an in-depth review of some of the key highlights from the Annual Hematology Conference satellite, Improving Outcomes in MDS and MPN: Tailoring Treatment Based on Patient- and Disease-Specific Factors, held as a live virtual symposium in December 2020. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with MDS and MPNs, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Agios Pharmaceuticals, Astex Pharmaceuticals, Bristol Myers Squibb, Gilead Sciences, Novartis, Taiho Oncology, and Takeda Oncology.

Target Audience

These activities are intended for hematologists and hematologist/oncologists interested in the treatment of patients with MDS and MPNs.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate safety and efficacy data regarding emerging treatment options and novel formulations in the management of MDS and MPNs.
• Develop an individualized plan of care based on risk stratification and symptom burden for patients with MDS and MPNs.
• Outline mechanisms of anemia in MDS and MPNs, and novel strategies to treat underlying anemia.
• Integrate emerging data into clinical scenarios to optimize care for patients with MDS and MPNs

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Guillermo Garcia-Manero, MD
Professor
Chief, Section of Myelodysplastic Syndromes
Deputy Chair, Translational Research
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Amphivena Therapeutics, Helsinn Therapeutics, Novartis Pharmaceuticals, AbbVie, Bristol Myers Squibb, Astex Pharmaceuticals, Onconova Therapeutics, H3 Biomedicine, Merck & Co., Curis, Janssen Pharmaceutica, Genentech, Forty Seven, Aprea Therapeutics.

Prithviraj Bose, MD
Associate Professor, Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant Research Support: Incyte, Celgene Corporation (now Bristol Myers Squibb), CTI BioPharma, Kartos Therapeutics, Constellation Pharmaceuticals, NS Pharma, Promedior; Consultant: Incyte, Celgene Corporation (now Bristol Myers Squibb), CTI BioPharma, Kartos Therapeutics.

Ruben A. Mesa, MD, FACP
Executive Director
Mays Cancer Center at UT Health San Antonio MD Anderson
Mays Family Foundation Distinguished University Presidential Chair
Professor of Medicine
University of Texas Health San Antonio MD Anderson Cancer Center
San Antonio, TX

Disclosures: Grant Research Support: bbVie, Celgene Corporation, CTI BioPharma, Imago Pharmaceuticals, Incyte Corporation, Sierra Oncology; Consultant: Bristol Myers Squibb, Imago Pharmaceuticals, Novartis, Protagonist Therapeutics, Sierra Oncology.

Valeria Santini
Associate professor of Hematology
Chair MDS Unit
Hematology
AOU Careggi
University of Florence

Disclosures: Consultant: Bristol Myers Squibb/Celgene, Geron Corporation, Menarini Group, Novartis, Takeda; Speakers Bureau: Bristol Myers Squibb/Celgene, Novartis.

Ayalew Tefferi, MD
Professor of Medicine
Division of Hematology
Mayo Clinic
Rochester, MN

Disclosures: No relevant financial relationships with commercial interests to disclose.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.